Neuroscience
From The New York Times:
Hopes for Alzheimer’s Drug Are Dashed
By ANDREW POLLACK
Published: March 4, 2010
Read the full article
- Alzheimer's Disease: Phase Ii Gammagard Findings
A report from the Alzheimer's Association International Conference (AAIC) in Vancouver: Alzheimer's drug IVIg could halt sufferers' decline Trial involving 16 patients excites scientists by suggesting treatment prevented deterioration of memory...
- Clinical Trials: Solanezumab In Alzheimer's Disease
From Bloomberg: Eli Lilly Shares Rise on Alzheimer’s Drug Hopes By Drew Armstrong and Robert Langreth Dec 6, 2011 [snip] "Solanezumab is an antibody designed to clear protein fragments called beta amyloid that clutter the brains of patients with Alzheimer’s...
- Alzheimer's Disease: Rethinking Things?
A very readable piece from Gina Kolata of the New York Times: Doubt on Tactic in Alzheimer’s Battle By GINA KOLATA The New York Times Published: August 18, 2010 "The failure of a promising Alzheimer’s drug highlights the gap between diagnosis and...
- Business World: Myriad Genetics, Flurizan (mpc-7869), And Alzheimer Disease
From the AP, via Yahoo! News: Largest-Ever Alzheimer's Drug Trial Begins By PAUL ELIAS, AP Biotechnology Writer Sun Mar 12, 6:58 AM ET SAN FRANCISCO - It's tragedy enough that Pat Williams' mother...
- Reminyl (galantamine Hydrobromide) (continued)
Safety Concerns Reported on J.& J. Alzheimer's Drug By ANDREW POLLACK New York Times Published: January 22, 2005 Regulators are reviewing the safety of the Alzheimer's disease drug Reminyl after data from two clinical trials indicated...
Neuroscience
Alzheimer Disease: Dimebon Results, Part II
From The New York Times:
Hopes for Alzheimer’s Drug Are Dashed
By ANDREW POLLACK
Published: March 4, 2010
"The drug, called Dimebon, failed in its first late-stage clinical trial, dealing a blow to patients with Alzheimer’s and the companies developing the treatment, Medivation and Pfizer."
Read the full article
- Alzheimer's Disease: Phase Ii Gammagard Findings
A report from the Alzheimer's Association International Conference (AAIC) in Vancouver: Alzheimer's drug IVIg could halt sufferers' decline Trial involving 16 patients excites scientists by suggesting treatment prevented deterioration of memory...
- Clinical Trials: Solanezumab In Alzheimer's Disease
From Bloomberg: Eli Lilly Shares Rise on Alzheimer’s Drug Hopes By Drew Armstrong and Robert Langreth Dec 6, 2011 [snip] "Solanezumab is an antibody designed to clear protein fragments called beta amyloid that clutter the brains of patients with Alzheimer’s...
- Alzheimer's Disease: Rethinking Things?
A very readable piece from Gina Kolata of the New York Times: Doubt on Tactic in Alzheimer’s Battle By GINA KOLATA The New York Times Published: August 18, 2010 "The failure of a promising Alzheimer’s drug highlights the gap between diagnosis and...
- Business World: Myriad Genetics, Flurizan (mpc-7869), And Alzheimer Disease
From the AP, via Yahoo! News: Largest-Ever Alzheimer's Drug Trial Begins By PAUL ELIAS, AP Biotechnology Writer Sun Mar 12, 6:58 AM ET SAN FRANCISCO - It's tragedy enough that Pat Williams' mother...
- Reminyl (galantamine Hydrobromide) (continued)
Safety Concerns Reported on J.& J. Alzheimer's Drug By ANDREW POLLACK New York Times Published: January 22, 2005 Regulators are reviewing the safety of the Alzheimer's disease drug Reminyl after data from two clinical trials indicated...